Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;23(4):737-9.
doi: 10.3346/jkms.2008.23.4.737.

Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy

Heekyoung Choi  1 , Su Jin Jeong, Han Sung Lee, Bum Sik Chin, Suk Hoon Choi, Sang Hoon Han, Myung Soo Kim, Chang Oh Kim, Jun Yong Choi, Young Goo Song, June Myung Kim
Affiliations

Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy

Heekyoung Choi et al. J Korean Med Sci. 2008 Aug.

Abstract

The combination of atazanavir (ATV) and lopinavir/ritonavir (LPV/RTV) with nucleoside reverse transcriptase inhibitors (NRTI) has been used as a salvage regimen for human immunodeficiency virus (HIV)-positive patients. In this paper, we discuss two cases of HIV-positive patients who had long histories of virological failure following a heavy treatment of antiretroviral drugs, but then achieved virological suppression with double-boosted protease inhibitor (PI) regimens. In patients with multiple genotypic resistance to PIs and NRTIs, virological suppression can be achieved with a combination of ATV plus LPV/RTV with an NRTI backbone. The two cases in this report suggest that a combination of ATV plus LPV/RTV could be a useful salvage regimen for the subset of HIV-positive patients with limited treatment options.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. - PubMed
    1. Loutfy MR, Walmsley SL. Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother. 2002;3:81–90. - PubMed
    1. Gallant JE. Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev. 2004;6:226–233. - PubMed
    1. Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocana I, Pahissa A. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising doubleboosted protease inhibitor regimen. AIDS. 2006;20:1131–1139. - PubMed
    1. Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis. 2005;18:1–7. - PubMed